To direct the Secretary of Health and Human Services to study and report on the relationship between hair straighteners and uterine cancer, particularly among women of color.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill directs the Secretary of Health and Human Services to conduct a 2-year study on the relationship between chemical hair straighteners and uterine cancer, with focus on women of color, and to determine whether FDA should. It relies on reporting requirements. The main policy areas are Health and Trade.
Who Benefits and How
Women of color and consumers of hair straightening products could face reduced risk.
Who Bears the Burden and How
Department of Health and Human Services / FDA / NIH would take on compliance duties.
Key Provisions
- Directs the Secretary of Health and Human Services to conduct a 2-year study on the relationship between chemical hair straighteners and uterine cancer, with focus on women of color, and to determine whether FDA should...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill directs the Secretary of Health and Human Services to conduct a 2-year study on the relationship between chemical hair straighteners and uterine cancer, with focus on women of color, and to determine whether FDA should.
Key Policy Areas
Health, Trade
Primary Purpose
The bill directs the Secretary of Health and Human Services to conduct a 2-year study on the relationship between chemical hair straighteners and uterine cancer, with focus on women of color, and to determine whether FDA should.
Policy Domains
Entire Bill
Identified Gains
- Women of color and consumers of hair straightening products
Identified Costs
- Department of Health and Human Services / FDA / NIH
Sponsors
Legislative Progress
IntroducedMs. Clarke of New York (for herself, Ms. Brown, Mrs. …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Women of color and consumers of hair straightening products
Department of Health and Human Services / FDA / NIH
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_director"
- → Director of the National Institutes of Health
- "the_secretary"
- → Secretary of Health and Human Services
- "the_commissioner"
- → Commissioner of Food and Drugs
Key Definitions
Terms defined in this bill
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology